Non-Small Cell Lung Cancer

Morning timing of immune checkpoint infusions is linked to better survival in metastatic non-small cell lung cancer, while other new drugs like magrolimab have not shown clear benefits.

Yes, a phase III trial (CALGB 140503) found sublobar resection noninferior to lobectomy for disease-free survival in small peripheral NSCLC ≤2 cm.

Bispecific antibodies and CAR T-cell therapy are two immunotherapies being tested for advanced NSCLC; bispecific antibodies show more clinical progress, while CAR T faces challenges like toxicity and tumor trafficking.

For advanced NSCLC, immunotherapy (especially pembrolizumab) is highly effective for high PD-L1 tumors, while chemotherapy remains a backbone; combining both may improve outcomes.

High PD-L1 expression (≥50%) often makes immunotherapy, such as pembrolizumab, a first-line option for advanced NSCLC, but other factors like mutations also guide treatment.

Global disparities in access to new NSCLC therapies stem from differences in drug approval, cost, testing infrastructure, and healthcare system resources.

In nonsquamous advanced NSCLC, camrelizumab was linked to a higher risk of disease progression and death than pembrolizumab in second-line or later treatment, based on one real-world study.

Yes, real-world data from over 17,500 patients shows pembrolizumab is effective as first-line treatment for advanced NSCLC with high PD-L1 (≥50%), with median overall survival of 21 months and 29% survival at 5 years.